Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma
Metadatos
Mostrar el registro completo del ítemAutor
Miguel-Pérez, Diego de; Bayarri Lara, Clara Isabel; Ortega, Francisco G.; Russo, Alessandro; Moyano Rodríguez, María José; Álvarez Cubero, María Jesús; Maza Serrano, Elizabeth; Lorente Acosta, José Antonio; Rolfo, Christian; Serrano, María JoséEditorial
MDPI
Materia
Circulating tumor cells Adenocarcinoma Liquid biopsy NSCLC AXL Prognosis
Fecha
2019-11-07Referencia bibliográfica
de Miguel-Pérez, D., Bayarri-Lara, C. I., Ortega, F. G., Russo, A., Moyano Rodriguez, M. J., Alvarez-Cubero, M. J., ... & Serrano, M. J. (2019). Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma. Cancers, 11(11), 1750.
Patrocinador
This work was supported by the Department of Health and SocialWelfare of the Regional Government of Andalusia [PI-0294-2012] and Diego de Miguel Perez was supported by the PhD (2014) and the PhD International Mobility (2019) grants from the University of Granada, Spain.Resumen
Background: The prognosis of early stage non-small cell lung cancer (NSCLC) is quite
disappointing and the benefits of adjuvant therapy are relatively small. Thus, there is an urgent
need to identify novel prognostic and predictive biomarkers. Lung adenocarcinoma has distinct
clinical–pathological characteristics and novel therapeutic strategies are under active evaluation
in the adjuvant setting. Here, we investigated the prognostic impact of circulating tumor cells
(CTCs) and gene and miRNA tissue expression in resectable NSCLC. Results: ADC (n = 47) and SCC (n = 50) revealed
different tissue expression profiles, resulting in the presence of different CTC subpopulations. In ADC,
miR-155 correlated with AXL and IL6R expression, which were related to the presence of EMT CTC1
(p = 0.014 and p = 0.004). In the multivariate analysis, CTC2 was an independent prognostic factor
for relapse-free survival, and CTC3 and AXL were independent prognostic for overall survival only
in ADC. Neither the surgery nor the adjuvant treatment influenced the prognosis of these patients.
Conclusions: Our study elucidate the prognostic impact of tissue AXL expression and the presence of
CTCs after surgery in adenocarcinoma patients. Tissue AXL expression and CTC EMT activation
could potentially represent biomarkers for the stratification of ADC patients that might benefit from
new adjuvant therapies.